Brief: Mithra And Rafa Laboratories Sign Binding Head Of Terms To Commercialize Donesta® In Israel

Mithra Pharmaceuticals SA

21/12/2023 16:53

Dec 21 (Reuters) - Mithra Pharmaceuticals SA  MITRA.BR :
    * MITHRA AND RAFA LABORATORIES SIGN BINDING HEAD OF TERMS TO
COMMERCIALIZE DONESTA® IN ISRAEL
    * LABORATORIES WILL HAVE EXCLUSIVE COMMERCIAL RIGHTS FOR
DONESTA®
IN ISRAEL AND PALESTINIAN TERRITORIES ON SIGNING OF FINAL
LICENSE AND SUPPLY AGREEMENT - PLANNED IN Q1 2024.
    * MITHRA IS ELIGIBLE TO RECEIVE A TOTAL OF EUR 2.05 MILLION
SALES-RELATED MILESTONES, ALONG WITH TIERED DOUBLE-DIGIT
ROYALTIES ON ANNUAL NET SALES.

Source text for Eikon:  ID:nGNX7vPJwv 
Further company coverage:  MITRA.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))